Company Description
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide.
The company’s principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.
It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI.
The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies.
It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels.
The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development.
Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
| Country | United States |
| Founded | 1980 |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| CEO | Robert Bradway |
Contact Details
Address: One Amgen Center Drive Thousand Oaks, California 91320-1799 United States | |
| Phone | 805 447 1000 |
| Website | amgen.com |
Stock Details
| Ticker Symbol | AMGN |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000318154 |
| CUSIP Number | 031162100 |
| ISIN Number | US0311621009 |
| Employer ID | 95-3540776 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Robert A. Bradway | Chairman, Chief Executive Officer and President |
| Peter H. Griffith | Executive Vice President and Chief Financial Officer |
| Dr. David M. Reese M.D. | Executive Vice President and Chief Technology Officer |
| Murdo Gordon | Executive Vice President of Global Commercial Operations |
| Dr. James E. Bradner M.D. | Executive Vice President of Research and Development |
| Esteban Santos | Executive Vice President of Operations |
| Matthew C. Busch | Chief Accounting Officer and Vice President of Finance |
| Scott Skellenger | Senior Vice President and Chief Information Officer |
| Dr. Howard Y. Chang M.D., Ph.D. | Senior Vice President of Global Research and Chief Scientific Officer |
| Justin G. Claeys | Vice President of Investor Relations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 2, 2025 | 144 | Filing |
| May 2, 2025 | 10-Q | Quarterly Report |
| May 1, 2025 | 8-K | Current Report |
| Apr 29, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 17, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 17, 2025 | SCHEDULE 13G/A | Filing |
| Apr 16, 2025 | PX14A6G | Notice of exempt solicitation submitted by non-management |
| Apr 9, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 9, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 2, 2025 | ARS | Filing |